Stay updated with breaking news from Nasdaq Clsd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock. Several other analysts also recently issued reports on the company. Wedbush restated an outperform rating and issued a $5.00 price objective on shares of […]
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial...
StockNews.com initiated coverage on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research note published on Saturday. The brokerage issued a sell rating on the stock. Several other equities analysts have also recently weighed in on CLSD. HC Wainwright restated a buy rating and issued a $6.00 price objective on shares of Clearside […]
StockNews.com assumed coverage on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a report published on Saturday. The firm issued a sell rating on the stock. A number of other research firms have also commented on CLSD. Needham & Company LLC reissued a buy rating and issued a $4.00 target price on shares of […]
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 382,900 shares, a growth of 45.4% from the August 31st total of 263,400 shares. Based on an average daily trading volume, of 111,600 shares, the days-to-cover […]